

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**20-947**

**APPROVAL LETTER**



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration  
Silver Spring MD 20993

NDA 020947

**NDA APPROVAL**

Nuvo Research Inc.  
2-1740 Lenape Road  
West Chester, PA 19382

Attention: Brad Galer  
U.S. Agent

Dear Dr. Galer:

Please refer to your new drug application (NDA) dated December 15, 1997, received December 16, 1997, which was withdrawn October 26, 1998, and resubmitted August 7, 2001, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for PENNSAID Topical Solution (diclofenac sodium topical solution) 1.5% w/w.

We acknowledge receipt of your submissions dated January 14, March 26 and 31, April 17 and 29, and July 31, 1998, and September 20 and October 5, 2001, and February 13, March 28, April 3, May 7 and 8, June 28, July 19 and 26, September 24, and November 7, 2002, and October 6, 2003, and June 28, August 17 (3), September 18 and 29, October 11, 12, 13, 23, 25, 26, and 27, and November 8 (2), 10 (2), and 15, 2006, and March 30, 2007, and February 4, April 27, June 11, 12, and 26, July 13, 14, 24, and 31, August 12 and 21, September 10 and 11, and October 2, 26, and 28, 2009.

The February 4, 2009 submission constituted a complete response to our December 28, 2006 action letter.

This new drug application provides for the use of PENNSAID Topical Solution (diclofenac sodium topical solution) for the relief of the signs and symptoms of osteoarthritis of the knee(s).

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is

identical to the enclosed labeling (text for the package insert and medication guide). For administrative purposes, please designate this submission, “**SPL for approved NDA 020947.**”

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.

### **CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (October 2005)*.

Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 020947.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for this application because necessary studies are impossible or highly impracticable. Osteoarthritis is an adult related condition that does not occur in children and qualifies for a waiver.

### **POSTMARKETING REQUIREMENTS UNDER 505(o)**

Section 505(o) of the FDCA authorizes FDA to require holders of approved drug and biological product applications to conduct postmarketing studies and clinical trials for certain purposes, if FDA makes certain findings required by the statute (section 505(o)(3)(A)).

We have determined that an analysis of spontaneous postmarketing adverse events reported under subsection 505(k)(1) of the FDCA will not be sufficient to identify an unexpected serious risk of enhanced tumorigenesis and/or reproductive toxicity related to the excipient dimethyl sulfoxide.

Furthermore, the new pharmacovigilance system that FDA is required to establish under section 505(k)(3) of the FDCA has not yet been established and is not sufficient to assess these serious risks.

Therefore, based on appropriate scientific data, FDA has determined that you are required, to conduct the following:

1566-1 An evaluation of the potential carcinogenicity of DMSO in a 2-year bioassay in the rat.

The timetable you emailed on October 23, 2009 states that you will conduct this study according to the following timetable:

Study Completion Date: by July 2011  
Final Report Submission: by August 2012

1566-2 An evaluation of Fertility and Early Embryonic Development in a single species with DMSO.

The timetable you emailed on October 28, 2009 states that you will conduct this study according to the following timetable:

Study Start Date: by June 2010  
Final Report Submission: by December 2010

1566-3 An evaluation of Peri-and Postnatal Development in a single species with DMSO.

The timetable you emailed on October 28, 2009 states that you will conduct this study according to the following timetable:

Study Start Date: by June 2010  
Final Report Submission: by September 2011

Submit the protocol to your IND, with a cross-reference letter to this NDA. Submit all final reports to your NDA. Prominently identify the submission with the following wording in bold capital letters at the top of the first page of the submission, as appropriate:

- **REQUIRED POSTMARKETING FINAL REPORT UNDER 505(o)**
- **REQUIRED POSTMARKETING CORRESPONDENCE UNDER 505(o)**

Section 505(o)(3)(E)(ii) of the FDCA requires you to report periodically on the status of any study or clinical trial required under this section. This section also requires you to periodically report to FDA on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Section 506B of the FDCA, as well as 21 CFR 314.81(b)(2)(vii) requires you to report annually on the status of any postmarketing commitments or required studies or clinical trials.

FDA will consider the submission of your annual report under section 506B and 21 CFR 314.81(b)(2)(vii) to satisfy the periodic reporting requirement under section 505(o)(3)(E)(ii) provided that you include the elements listed in 505(o) and 21 CFR 314.81(b)(2)(vii). We remind you that to comply with 505(o), your annual report must also include a report on the status of any study or clinical trial otherwise undertaken to investigate a safety issue. Failure to submit an annual report for studies or clinical trials required under 505(o) on the date required will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action.

### **RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS**

Section 505-1 of the FDCA authorizes FDA to require the submission of a Risk Evaluation and Mitigation Strategy (REMS) if FDA determines that such a strategy is necessary to ensure that the benefits of the drug outweigh the risks (section 505-1(a)).

Your proposed REMS, submitted on October 26, 2009, and appended to this letter, is approved. The REMS consists of the Medication Guide included with this letter and the timetable for submission of assessments of the REMS.

The REMS assessment plan should include but is not limited to an evaluation of patients' understanding of the serious risks of PENNSAID Topical Solution (diclofenac sodium topical solution).

You should submit the final methodology and content of the patient survey at least 90 days prior to initiating the conduct of the survey.

The requirements for assessments of an approved REMS under section 505-1(g)(3) include, in section 505-1(g)(3)(B) and (C), requirements for information on the status of any post approval study or clinical trial required under section 505(o) or otherwise undertaken to investigate a safety issue. You can satisfy these requirements in your REMS assessments by referring to relevant information included in the most recent annual report required under section 506B and 21 CFR 314.81(b)(2)(vii) and including any updates to the status information since the annual report was prepared. Failure to comply with the REMS assessments provisions in 505-1(g) could result in enforcement action.

We remind you that in addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in Section 505-1(g)(2)(A) of FDCA.

Prominently identify submissions containing REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission:

**NDA 020947  
REMS ASSESSMENT**

**NEW SUPPLEMENT FOR NDA 020947  
PROPOSED REMS MODIFICATION  
REMS ASSESSMENT**

**NEW SUPPLEMENT FOR (NEW INDICATION FOR USE)  
FOR NDA 020947  
REMS ASSESSMENT  
PROPOSED REMS MODIFICATION (if included)**

If you do not submit electronically, please send 5 copies of REMS-related submissions.

**PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

**EXPIRATION DATING PERIOD**

An expiry of 18 months is granted for the 15-mL and 60-mL bottles and an expiry of 15 months is granted for the 150-mL bottles under the recommended storage conditions: Store upright under conditions of 25°C (77°F); excursions permitted to 15 to 30°C (59 to 86°F) [see USP Controlled Room Temperature].

**LETTERS TO HEALTH CARE PROFESSIONALS**

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA, to [CDERMedWatchSafetyAlerts@fda.hhs.gov](mailto:CDERMedWatchSafetyAlerts@fda.hhs.gov), and to the following address:

MedWatch  
Food and Drug Administration  
Suite 12B-05  
5600 Fishers Lane  
Rockville, MD 20857

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Jessica Benjamin, Regulatory Project Manager, at (301) 796-3924.

Sincerely,

*{See appended electronic signature page}*

Bob A. Rappaport, M.D.  
Director  
Division of Anesthesia, Analgesia  
and Rheumatology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosure: Package Insert  
Medication Guide  
Patient Instruction for Use  
REMS  
Carton and Immediate Container Labeling

Application  
Type/Number

Submission  
Type/Number

Submitter Name

Product Name

-----  
NDA-20947

-----  
ORIG-1

-----  
NUVO RESEARCH  
INC

-----  
PENNSAID(DICLOFENAC  
SODIUM)1.5% TOP LOTI

-----  
**This is a representation of an electronic record that was signed  
electronically and this page is the manifestation of the electronic  
signature.**  
-----

/s/  
-----

BOB A RAPPAPORT  
11/04/2009